Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography
Open Access
- 1 April 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 77 (4) , 508-516
Abstract
Alzheimer disease (AD) includes a decades-long period of pathologic changes leading to dementia onset.1,2 To improve and rationalize the early detection of disease, the AD community is considering a biology-based disease classification relying principally on evidence of characteristic AD amyloid-β (Aβ) and tau pathologies.3 Such evidence can come from analysis of cerebrospinal fluid (CSF) or positron emission tomography (PET). Because these modalities are not typically available simultaneously, their results are often used interchangeably. However, CSF and PET indicators of Aβ pathology appear to provide overlapping, but not identical, information.4,5 Thus, some have suggested that CSF Aβ abnormality may precede Aβ-PET positivity.6 Discordance of these 2 biomarker measures may therefore indicate different stages of disease progression.Keywords
This publication has 44 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)Brain Imaging and Behavior, 2012
- A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairmentBrain Imaging and Behavior, 2012
- Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal SubjectsJournal of Nuclear Medicine, 2012
- Use of Florbetapir-PET for Imaging β-Amyloid PathologyJAMA, 2011
- No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's diseaseBrain, 2007
- No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's diseaseBrain, 2007
- CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's diseaseBrain, 2006
- Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's diseaseNeurology, 1992
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991